Bio-Techne Corp. plans to sell its Exosome Diagnostics Inc. business to Mdxhealth SA for $15 million plus royalty payments, a steep cut from the $250 million the company paid to acquire Exodx in 2018.
MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx ...
IRVINE, CA, and HERSTAL, BELGIUM – August 5, 2025 (GlobeNewswire) – MDxHealth SA (MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced preliminary financial ...
Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. academic funding weighed on demand for its drug-development products.
MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of ...
Bio-Techne’s strategy involves prioritizing top line growth with manufacturing capacity investment and large-scale customer deals, while complementing organic growth with meaningful acquisitions. The ...
Bio-Techne TECH is making notable strides in its four growth verticals, which are poised to help it grow in the upcoming quarters. The company is now pursuing clinical diagnostic opportunities on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results